Prion diseases - Current theories and potential therapies: A brief review

Folia Neuropathologica

Volumn 50, Issue 1, 2012, Pages 46-49

  Marandi, Yasser ^a   Farahi, Neda ^b   Sadeghi, Amin ^c   Sadeghi Hashjin, Goudarz ^c  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Current theories; Potential therapies; Prion diseases

Indexed keywords

CALCINEURIN; CHLORPROMAZINE; FLUPIRTINE; MEPACRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRION PROTEIN;

BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; CELL MATURATION; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; GENE SILENCING; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OVARY FOLLICLE CELL; PATHOLOGY; PRION DISEASE; PROTEIN DOMAIN; PROTEIN FOLDING; REVIEW; RNA INTERFERENCE;

EID: 84860328186     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Alvarez-Buylla A, Herrera DG, Wichterle H. The subventricular zone: source of neuronal precursors for brain repair. Prog Brain Res 2000; 127: 1-11. (Pubitemid 35461253)
2. Belay ED. Transmissible spongiform encephalopathies in humans. Annu Rev Microbiol 1999; 53: 283-314. (Pubitemid 29503733)
3. Bruce ME, Will RG, Ironside JW, McConell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501. (Pubitemid 27435325)
4. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-690. (Pubitemid 26360638)
5. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52: 503-506.
6. Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 2003; 116: 2775-2779. (Pubitemid 36857228)
7. Gregori L. A prototype assay to detect vCJD-infected blood. Lancet 2011; 377: 444-446.
8. Hussein MF, Al-Mufarrej SI. Prion Diseases: A Review; II. Prion Diseases in Man and Animals. Sci J King Faisal Uni (Basic Appl Sci) 2004; 5: 139-166.
9. Klingenstein R, Löber S, Kujala P, Godsave S, Leliveld SR, Gmeiner P, Peters PJ, Korth C. Tricyclic antidepressants, qui nacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 2006; 98: 748-759. (Pubitemid 44051276)
10. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98: 9836-9841. (Pubitemid 32769390)
11. Mabbott NA, Young J, McConnell I, Bruce ME. Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J Virol 2003; 77: 6845-6854. (Pubitemid 36666878)
12. McKay R. Stem cells in the central nervous system. Science 1997; 276: 66-71. (Pubitemid 27161244)
13. Mouillet-Richard S, Pietri M, Schneider B, Vidal C, Mutel V, Launay JM, Kellermann O. Modulation of serotonergic receptor signalling and cross-talk by prion protein. J Biol Chem 2005; 280: 4592-4601. (Pubitemid 40288627)
14. Mukherjee A, Morales-Scheihing D, Gonzalez-Romero D, Green K, Taglialatela G, Soto C. Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival. PLoS Pathog 2010; 6: e1001138.
15. Müller WEG, Ushijima H, Schröder HC, Forrest JMS, Schatton WFH, Rytik PG, Heffner-Lauc M. Cytoprotective effect of N-me thyl-Daspartate receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell culture. Eur J Pharmacol 1993; 246: 261-267. (Pubitemid 23253684)
16. Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, Yamauchi A, Kataoka Y. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004; 17: 158-163. (Pubitemid 38339741)
17. Nicoll AJ, Trevitt CR, Tattum MH, Risse E, Quarterman E, Ibarra AA, Wright C, Jackson GS, Sessions RB, Farrow M, Waltho JP, Clarke AR, Collinge J. Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci USA 2010; 107: 17610-17615.
18. Nikanfar M, Farhoudi M, Halimi M, Ashrafian-Bonab F, Mehrvar K. Creutzfeldt-Jakob Disease Presenting with Confusion and Visual Disturbance. Arch Iran Med 2007; 10: 397-400. (Pubitemid 47162543)
19. Park KI, Teng YD, Snyder EY. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat Biotechnol 2002; 20: 1111-1117. (Pubitemid 35285439)
20. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA, Burton DR, Prusiner SB. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739-743. (Pubitemid 32771997)
21. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 2006; 116: 3204-3210. (Pubitemid 44878634)
22. Schröder HC, Müller WEG. Neuroprotective effect of flupirtine in prion disease. Drugs Today (Barc) 2002; 38: 49-58. (Pubitemid 34225788)
23. Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL. Efficient and specific downregulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003; 305: 548-551. (Pubitemid 36579265)
24. Vidal C, Herzog C, Haeberle AM, Bombarde C, Miquel MC, Carimalo J, Launay JM, Mouillet-Richard S, Lasmézas C, Dormont D, Kellermann O, Bailly Y. Early dysfunction of central 5-HT system in a murine model of bovine spongiform encephalopathy. Neuroscience 2009; 160: 731-743.
25. Weissmann C. Spongiform encephalopathies. The prion's progress. Nature 1991; 349: 569.
26. Weissmann C. Thoughts on mammalian prion strains. Folia Neuropathol 2009; 47: 104-113.
27. Weissmann C, Aguzzi A. Approaches to therapy of prion diseases. Annu Rev Med 2005; 56: 321-344. (Pubitemid 40299786)
28. Whatley SA, Powell JF, Politopoulou G, Campbell IC, Brammer MJ, Percy NS. Regulation of intracellular free calcium levels by the cellular prion protein. NeuroReport 1995; 6: 2333-2337. (Pubitemid 26013122)
29. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422: 80-83. (Pubitemid 36323299)
30. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008; 105: 10238-10243.